Indolent Lymphomas

  • Thomas M. HabermannEmail author


Non-Hodgkin lymphomas (NHL) may be aggressive or indolent (“low-grade”). The paradox is that aggressive lymphomas are potentially curable, and patients who do not respond to initial therapy have a worse prognosis and short survival time. In contrast, the majority of patients with indolent lymphoma are not curable, respond to many different therapeutic interventions, and live a long period of time. Indolent follicular lymphomas arise from cells that populate lymph nodes and the bone marrow but may also involve extranodal sites. The World Health Organization (WHO) classification does not divide lymphomas by grade, and because they are not indolent, the preferred name used is “small B-cell lymphomas” in the most recent classification. The small B-cell lymphomas discussed in this section include follicular lymphoma (FL) (follicular lymphoma, in situ follicular lymphoma, duodenal-type FL, and predominantly diffuse follicular lymphoma with 1p36 deletion), nodal marginal zone lymphoma, splenic marginal zone lymphoma, extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) lymphoma, lymphoplasmacytic lymphoma/Waldenström macroglobulinemia, and primary cutaneous follicle center lymphoma. The updated and revised edition of the 2008 WHO classification was published in a paper in 2016 with a revised edition of the book released in 2017 (Swerdlow et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC, 2008; Swerdlow et al. Blood 127:2375–2390, 2016). The prognosis and treatment are dependent upon the histology, stage, amount or bulk of disease, symptoms, and other factors.


Non-Hodgkin lymphoma (NHL) Follicular lymphoma (FL) Marginal zone lymphoma (MZL) MALT lymphoma Lymphoplasmacytic lymphoma/Waldenström macroglobulinemia (LPL/WM) Lymphadenopathy Ann Arbor staging Apoptosis Immunochemotherapy Rituximab Bendamustine 

Suggested Reading

  1. 1.
    Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008.Google Scholar
  2. 2.
    Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–90.CrossRefGoogle Scholar
  3. 3.
    Al-Hamadani M, Habermann TM, Cerhan JR. Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: a longitudinal analysis of the National Cancer Data Base from 1998 to 2011. Am J Hematol. 2015;90:790–5.CrossRefGoogle Scholar
  4. 4.
    Teras LR, DeSanto GE, Cerhan JR, et al. 2016 US lymphoid malignancy status in WHO subtypes. CA Cancer J Clin. 2016;66:443–59.CrossRefGoogle Scholar
  5. 5.
    Linet MS, Vajdic CM, Morton LM, et al. Medical history, lifestyle, family history, and occupational risk factors for follicular lymphoma: the InterLymph non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr. 2014;48:26–40.CrossRefGoogle Scholar
  6. 6.
    Habermann TM, Steensma DP. Lymphadenopathy. Mayo Clin Proc. 2000;75:723–32.CrossRefGoogle Scholar
  7. 7.
    Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between and initial no treatment policy, prednimustine, and interferon alfa: a randomized study from the Groupe d’Edude des Lymphomes Folliculares-Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 1997;15:1110–7.CrossRefGoogle Scholar
  8. 8.
    Ardeshna KM, Qian W, Smith P, et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomized phase 3 trial. Lancet Oncol. 2014;15:424–35.CrossRefGoogle Scholar
  9. 9.
    Kahl BS, Hong F, Williams ME, et al. Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: Eastern Cooperative Oncology Group protocol E4402. J Clin Oncol. 2014;32:3096–102.CrossRefGoogle Scholar
  10. 10.
    Wagner LI, Zhao F, Hong F, et al. Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: results from ECOG trial E4402 (RESORT). J Clin Oncol. 2015;33:740–8.CrossRefGoogle Scholar
  11. 11.
    Friedberg JW, Taylor MD, Cerhan JR, et al. Follicular lymphoma in the United States: first report of the National LymphoCare Study. J Clin Oncol. 2009;27:1202–8.CrossRefGoogle Scholar
  12. 12.
    Link BK, Maurer MJ, Nowakowski G, et al. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource. J Clin Oncol. 2013;31:3272–8.CrossRefGoogle Scholar
  13. 13.
    Maurer MJ, Bachy E, Ghesquiéres H, et al. Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. Am J Hematol. 2016;91:1096–101.CrossRefGoogle Scholar
  14. 14.
    Nooka AK, Nabhan C, Zhou X, et al. Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices. Ann Oncol. 2013;24:441–8.CrossRefGoogle Scholar
  15. 15.
    Villa D, Crump M, Panzarella T, et al. Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group. J Clin Oncol. 2013;31:1164–71.CrossRefGoogle Scholar
  16. 16.
    Al Khabori M, de Almeida JR, Guyatt GH, et al. Autologous stem cell transplantation in follicular lymphoma: a systemic review and meta-analysis. J Natl Cancer Inst. 2012;104:18–28.CrossRefGoogle Scholar
  17. 17.
    van Besien K, Loberiza FR Jr, Bajorunaite R, et al. Comparison of autologous and allogeneic stem cell transplantation for follicular lymphoma. Blood. 2003;102:3521–9.CrossRefGoogle Scholar
  18. 18.
    Salles GA, Morschhauser F, Solal-Celigny P, et al. Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study. J Clin Oncol. 2013;31:2920–6.CrossRefGoogle Scholar
  19. 19.
    Sehn LH, Chua N, Mayer J, et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomized, open-label, multicenter, phase 3 trial. Lancet Oncol. 2016;17:1081–8.CrossRefGoogle Scholar
  20. 20.
    Witzig TE, Nowakowski GS, Habermann TM, et al. A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma. Ann Oncol. 2015;26:1667–77.CrossRefGoogle Scholar
  21. 21.
    Witzig TE, Nowakowski GS, Habermann TM, et al. Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma. Am J Hematol Accepted July 11. 2017. Scholar
  22. 22.
    Fowler N, Nastoupil L, de Vos S, et al. Ibrutinib plus rituximab in treatment-Naïve patients with follicular lymphoma: results from a multicenter, phase 2 study. Blood. 2015;126:470. Abstract 2015.Google Scholar
  23. 23.
    Fowler NH, Davis RE, Rawal S, et al. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol. 2014;15:1311–8.CrossRefGoogle Scholar
  24. 24.
    Davids MS, Roberts AW, Seymour JF, et al. Phase 1 first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol. 2017. Scholar
  25. 25.
    Lowry L, Smith P, Qian W, et al. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomized phase III trial. Radiother Oncol. 2011;100:85–92.CrossRefGoogle Scholar
  26. 26.
    Correia C, Schneider PA, Dai H, et al. BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma. Blood. 2015;125:658–67.CrossRefGoogle Scholar
  27. 27.
    Zucca E, Copie-Bergman C, Ricardi U, et al. Gastric marginal zone lymphoma of MALT type: ESMO clinical practice guidelines for diagnosis, treatment, and follow-up. Ann Oncol. 2013;24(Supplement 6):vi144–8.PubMedGoogle Scholar
  28. 28.
    Zullo A, Hassan C, Cristofari F, et al. Effects of Helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma. Clin Gastroenterol Hepatol. 2010;8:105–10.CrossRefGoogle Scholar
  29. 29.
    Schechter NR, Portlock CS, Yahalom J, et al. Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone. J Clin Oncol. 1998;16:1916–21.CrossRefGoogle Scholar
  30. 30.
    Martinelli G, Laszlo D, Ferreri AJ, et al. Clinical activity of rituximab in gastric marginal zone non-Hodgkin lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol. 2005;23:1979–83.CrossRefGoogle Scholar
  31. 31.
    Sammassimo S, Pruneri G, Andreola G, et al. A retrospective international study on primary extranodal marginal zone lymphoma of the lung (BALT lymphoma) on behalf of International Extranodal Lymphoma Study Group (IELSG). Hematol Oncol. 2016;34:177–83.CrossRefGoogle Scholar
  32. 32.
    Jackson ME, Mian M, Kalpakais CH, et al. Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue of the salivary glands: a multicenter, international experience of 248 patients (IELSG 41). Oncologist. 2015;20:1149–53.CrossRefGoogle Scholar
  33. 33.
    Taner T, Nagorney DM, Tefferi A, et al. Splenectomy for massive splenomegaly. Ann Surg. 2013;258:1034–9.CrossRefGoogle Scholar
  34. 34.
    Williams ME, Hong F, Gascoyne RD, et al. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. Br J Haematol. 2016;173:867–75.CrossRefGoogle Scholar
  35. 35.
    Kapoor P, Ansell SM, Fonseca R, et al. Diagnosis and management of Waldenström macroglobulinemia Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines 2016. JAMA Oncol. 2017. Epub ahead of print.CrossRefGoogle Scholar
  36. 36.
    Treon SP, Tripas CK, Meid K, et al. Ibrutinib in previously treated Waldenström’s Macroglobulinemia. N Engl J Med. 2015;372:1430–40.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Mayo Clinic, Division of HematologyRochesterUSA

Personalised recommendations